Dr. Brad Thompson
Kickshaw Ventures Ltd., and and Wyvern Pharmaceuticals Inc. CEO
Dr. Thompson is an experienced biotechnology company founder and company executive, currently CEO at Kickshaw Ventures Ltd., and Wyvern Pharmaceuticals Inc., and formerly CEO of Oncolytics Biotech, Inc., from 1999 to 2016 and CEO of Synsorb Biotech from 1994 to 1999. He has served as Chairman, Director and Audit Committee member on a number of other public company (NASDAQ, TSX, CDNX) boards of directors, and private company boards and industry groups (including Chairman and Chairman Emeritus of BIOTECanada). He received his Ph.D. from the University of Western Ontario in the Department of Microbiology and Immunology.
Full body skin regeneration therapy to be introduced at RAADfest for the first time.
We are researching the longevity effects of full skin regeneration (epidermis, dermis, and subcutaneous layers including dendritic and stem cell progenitor cell populations). We will convey what benefits to lifespan extension can be expected by focusing on regenerating whole organ systems.
“This therapy will not only have a full regenerative effect on the skin , but will have a cascading positive effect on building the immune system and extending human life. It will be FDA approved and the human trials will be fully funded by Wyvern Pharmaceuticals and Kickshaw Ventures inc.”-- Dr. Thompson.